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Selection of the most appropriate experimental conditions for a particular analysis
can be a very tedious and time consuming process. Researchers are abandoning the old-
-fashioned, classical approach one-factor-at-a-time and substituting it with modern, ad-
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This paper presents the chemometrically assisted optimi-
zation and validation of the RP-HPLC method intended
for the quantitative analysis of itraconazole and its im-
purities in pharmaceutical dosage forms. To reach the
desired chromatographic resolution with a limited num-
ber of experiments in a minimum amount of time, Box-
-Behnken design was used to simultaneously optimize
some important chromatographic parameters, such as the
acetonitrile content in the mobile phase, pH of the aqueous
phase and the column temperature. Separation between
itraconazole and impurity F was identified as critical
and selected as a response during the optimization. The
set optimal mobile phase composition was acetonitri-
le/water pH 2.5 adjusted with o-phosphoric acid (50:50,
V/V). Separations were performed on a Zorbax Eclipse
XDB-C18, 4.6 ´ 150 mm, 5 m particle size column with
the flow rate 1 mLmin–1, column temperature set at 30 °C
and UV detection at 256 nm. The established method was
then subjected to method validation and the required va-
lidation parameters were tested. For the robustness eva-
luation, fractional factorial 24–1 design was utilized and
factors that might significantly affect the system perfor-
mance were defined. As other validation parameters
were also found to be suitable, the possibility to apply
the proposed method for the determination of itracona-
zole, its impurities B and F in any laboratory under dif-
ferent circumstances has been proven.
Keywords: itraconazole, itraconazole impurities, high per-
formance liquid chromatography, Box-Behnken design,
fractional factorial design
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vanced approaches. Namely, for the selection of the region where the response exhibits
the optimum, utilization of experimental design gained considerable attention and as
the most convenient three-level factorial designs, such as central composite design, Box-
-Behnken (BBD) design or Doehlert matrix, are usually applied (14). Furthermore, ex-
perimental design became inevitable in proper planning and conducting of robustness
testing (58). In this paper, optimization and validation of the reversed-phase high per-
formance liquid chromatographic (RP-HPLC) method, suitable for the separation of itra-
conazole from its impurities, was supported by the appropriate experimental design: Box-
-Behnken design was employed at the optimization step, while in the robustness evalua-
tion of fractional factorial design enabled anticipation of the system behaviour under
real operational conditions.
Chemical structures and chemical names of the analyzed substances are given in
Fig. 1. Although, impurities B and F are process related impurities of itraconazole, they
are specified by formulation manufacturers as the impurities to be analyzed during shelf
life.
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Fig. 1. Chemical structures of: a) itraconazole (2R,4S)-rel-1-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-di-
chlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl)-
4,5-dihydro-1H-1,2,4-triazol-5-one, b) impurity B (2R,4S)-rel-1-{butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-
(2,4-dichlorophenyl)-2-{1H-1,3,4-triazol-1-ylmethyl)1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-






In order to support the defined aim, a literature survey was done. The official method,
given in Eur. Ph. 7 (9) describes the gradient mode RP-HPLC method for the separation
of itraconazole and its seven impurities. Then, chromatographic behavior of itraconazole
and its twelve impurities was analyzed, on four stationary phases varying the pH of the
mobile phase in order to define the linear mathematical models for the prediction of im-
purities' retention times (10). Many HPLC methods for the analysis of itraconazole and
hydroxyitraconazole in serum and plasma with UV detection were described (1115).
For the purpose of bioavailability and bioequivalence studies of itraconazole, HPLC-tan-
dem mass spectrometry (16), as well as HPLC methods employing either UV (17) or flu-
orescence detection (18) were used. Itraconazole, voriconazole and posaconazole in hu-
man plasma were determined by the HPLC method coupled with a single mass detector
(19). Also, novel itraconazole-loaded intravenous nanoparticles were evaluated on the ba-
sis of itraconazole and hydroxyitraconazole assay by the HPLC method with UV detection
(20). For the determination of ketoconazole, tioconazole, econazole, miconazole and itra-
conazole in cosmetic antidandruff shampoos and lotions, the HPLC method with UV
detection was used (21).
According to the literature review, the only citations dealing with itraconazole and
its impurities are Ph. Eur. 7 (9) and a study done by Dumarey et al. (10). Ph. Eur. 7 pre-
sents the gradient elution mode RP-HPLC method for the analysis of impurities only in
pharmaceutical substances, with mobile phase comprising tetrabutylammonium hydro-
gen sulfate. The method given in the Ph. Eur. 7 was developed for the analysis of seven
impurities. However, when only two impurities are of interest, a simpler method could
be defined in order to shorten the analysis time and to enable utilization of simple mo-
bile phase. The authors set as their goal the development and chemometrically support-
ed optimization and validation of the method adequate for the quantitative analysis of
itraconazole and its impurities B and F in pharmaceutical dosage forms, e.g., capsules.
Accordingly, a systematic approach was applied; it was started with consideration of the
most suitable starting chromatographic conditions.
EXPERIMENTAL
Chemicals
Working standards of itraconazole, impurities B and F (Chemo, Quimica Sintética,
Spain) were used to prepare solutions for the optimization and validation of the propos-
ed method. All reagents used were of analytical grade. Acetonitrile HPLC grade (ACN)
(Sigma, USA) and water – HPLC grade were used to prepare mobile phase, while the
o-phosphoric acid (Carlo Erba, Italy) was used to adjust pH of the mobile phase. Work-
ing standards (itraconazole, impurity B and impurity F) were of Eur. Ph. quality. The ana-
lyzed pharmaceutical dosage form was Omicral® capsules (Medico Uno, Serbia), con-
taining 100 mg of itraconazole.
RP-HPLC conditions
The chromatographic system Waters Breeze (USA) consisted of a Waters 1525 Binary
HPLC Pump, Waters 2487 UV/VIS dual absorbance detector and Breeze Software Win-
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dows XP for data collection. Separations were performed on a Zorbax Eclipse XDB-C18
(4.6 ´ 150 mm), 5 mm particle size column (Agilent Technologies, USA). UV detection
was performed at 256 nm. The samples were introduced through a Rheodyne injector
(USA) valve with a 20-mL sample loop.
Mobile phases for the optimization were prepared according to the plan of experi-
ments set by the Box-Behnken design (Table I). The resulting mobile phases were filtered
through a 0.45-mm membrane filter (Alltech, Belgium).
The optimal mobile phase composition was: acetonitrile/water pH 2.5 adjusted with
o-phosphoric acid (50:50, V/V). Flow rate was 1 mL min–1 and the column temperature
was 30 °C.
Standard solutions
Stock solutions of itraconazole (1 mg mL–1), impurity B (10 mg mL–1) and impurity F
(10 mg mL–1) were prepared in a mixture of methanol/tetrahydrofuran (50:50, V/V). Cor-
responding stock solutions were diluted with a mixture of acetonitrile/water pH 2.5 ad-
justed with o-phosphoric acid (50:50, V/V) to prepare a mixture containing 200 mg mL–1
of itraconazole and 1 mg mL–1 of each impurity.
To prove the selectivity of the proposed RP-HPLC method, a placebo mixture was
prepared in methanol/tetrahydrofuran (50:50, V/V) at the concentration ratio corres-
ponding to the content in capsules. It was treated in the same manner as capsule powder
used for the preparation of sample solution. Sample solution containing 200 mg mL–1 of
itraconazole was used for selectivity assessment.
For linearity testing from the stock solution, six solutions containing itraconazole
were prepared in the mobile phase in the concentration range from 20 to 500 mg mL–1.
Six solutions containing 0.1 to 2.5 mg mL–1 of each impurity were obtained by diluting
stock solutions with the mobile phase.
Sample solution, solutions for estimating precision and accuracy
For two different commercially available batches, the mass of the-ten-capsule con-
tent was determined. Then the quantity of the capsule powder corresponding to 50 mg
of itraconazole was placed into a 50-mL volumetric flask and extracted with the metha-
nol/tetrahydrofuran mixture (50:50 V/V) using an ultrasonic bath during 20 min. After
filtration, clear filtrate was diluted with the mobile phase to prepare a series of six solu-
tions containing 200 g mL-1 of itraconazole. These solutions were used for estimating
the precision as well.
A laboratory mixture containing placebo (saccharose, maydis starch, purified water,
Poloxamer 188 and hypromeloze), itraconazole and its impurities was prepared in the
methanoltetrahydrofuran mixture (50:50, V/V) in the ratio corresponding to the investi-
gated tablets. Laboratory mixture was treated in the same manner as the capsule powder
used for the preparation of solutions for estimating the precision. For quantitative analy-
sis of the laboratory mixture, three series of dilutions, calculated as 80, 100 and 120 % of the
concentrations corresponding to those in capsules, were prepared, with three solutions
for each concentration:
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mixture (1) contained 160 g mL–1 of itraconazole and 0.8 g mL–1 of each impurity (80
%), mixture (2) contained 200 g mL–1 of itraconazole and 1.0 g mL–1 of each impurity
(100 %), mixture (3) contained 240 g mL–1 of itraconazole and 1.2 g mL–1 of each im-
purity (120 %).
RESULTS AND DISCUSSION
When a new separation problem is faced, starting decisions concerning the type of
stationary phase, solvent type and water phase nature should be made. These factors are
usually selected based on prior knowledge or screening studies. According to high lipo-
philic properties of the analyzed substances, acetonitrile was selected as organic modi-
fier in the mobile phase. Moreover, itraconazole and its impurities B and F are basic drugs
with minor differences between their structures. At the side chain, itraconazole and im-
purity F possess butyl, impurity B 1-methylpropyl group and also triazole ring are at-
tached in impurity B to position 1,2,4-triazol-4-yl, whereas in itraconazole and impurity
F to position 1,2,4-triazol-1-yl. In order to solve the problem of separation of quite simi-
lar substances, a Zorbax Eclipse XDB-C18 column containing extra densely bonded and
doubled endcapped stationary phase was chosen. In general, the application of such a
stationary phase does not usually demand utilization of ion-pairing reagents or other
additives in the mobile phase adjustment of the pH of the aqueous phase.
Method optimization
At the next step, readily adjustable factors with a significant effect on selectivity, re-
tention or resolution should be examined in more detail. In RP-HPLC, these factors are
usually the concentration of organic solvent, temperature and aqueous phase pH which
should be set to optimal values to succeed in separation. The most efficient way of set-
ting the optimal region is to apply one of the available response surface designs. For this
purpose, three level designs should be used and the most widely used are central com-
posite design and Box-Behnken design. Three level designs are recommendable as they
enable determination of a critical point (maximum, minimum, or saddle) in the response
surface. Namely, the resulting polynomial function will contain linear, interactions and
quadratic terms and have the following form:
y = b0 + b x
k
i ii  1
+ b xk ii ii
2
1
+ b x xk iji j i j1  + e (1)
where k is the number of variables, b0 is the constant term, bi represents the coefficients
of the linear parameters, bij represents the coefficient of interaction parameters, bii repre-
sents the coefficient of quadratic terms, xi represents the variables and e is the residual
associated with the experiments.
In this study, Box-Behnken design was selected for the estimation of parameters in
Eq. (1). It is based on three-level incomplete factorial designs. This design consists of
three parts of four runs and replications at the central point. Within each part, two factors
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are arranged in a full two-level design, while the level of the third factor is set at zero
(22). For three examined factors, this design requires twelve experiments, plus central
point replications. Also, BBD is nearly rotable and particularly useful when the points
on one or more corners of the cube represent factor-level combinations that are unaccept-
ably expensive or impossible to test due to physical constraints on the experimentation (23).
Acetonitrile content, pH of the aqueous phase and column temperature were select-
ed as the independent variables, and I/impF –  value of itraconazole and impurity F as
the dependent variable. The response  value was selected based on the fact that between
itraconazole and impurity F, which represent the critical pair, there is a great difference
in peak heights. Realistic evaluation of the overall separation of these peaks could not be
obtained by calculating RI/impF as the determination of peak width demands the construc-
tion of tangents and small variations in the slope imply large variations in the width. q cri-
terion was suggested by Carle (24) who suggested the mathematical equation, which was
derived from Kaiser’s equation (25) for the peak-to-valley ratio:
qs,l = 1 – ((Hn  |tR,l – tR,s |)/(|tR,n – tR,s |  (Hl – Hs) + Hs  |tR,l – tR,s|)) (2)
where Hs and Hl are peak heights, Hv is the valley height, tR,s and tR,l are the retention
times of the peaks, and tR,v is the time position of the valley as it is presented in Fig. 2.
s,l varies between 0, when peaks are completely overlapped, and 1, when peaks are se-
parated at the baseline.
At the next step, the experiments were conducted according to the plan of experi-
ments and the obtained data are presented in Table I. Experimental design plan was de-
fined and data analysis and calculations were performed using Design-Expert® 7.0.0.
(Stat-Ease Inc., Minneapolis).
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Fig. 2. Parameters for the calculation of q criterion from Kaiser’s equation.
Quadratic response model was suggested as the most adequate for the response
I/impF. The calculated coefficients of the response model for coded factor levels are
given in Table II.
As it was expected, factor A (acetonitrile content) had the largest influence on the
responses. The previously mentioned fact about the high lipophilicity of the analytes can
easily explain the decrease of response values with the increase in the acetonitrile con-
tent in the mobile phase and the minus sign is assigned to the corresponding coefficient
(b1). Response I/impF was not influenced by factors B (pH of the aqueous phase) and C
(column temperature) at all.
In order to carry out deeper analysis of acetonitrile and pH of the aqueous phase
influence, 3D graph was constructed. It was obtained by plotting I/impF on the z-axis
and acetonitrile content on x-axis, while the pH of the aqueous phase was on the y-axis.
It was observed that the acetonitrile content should be set at 50 %, as the lowering
of the I/impF value is quite abrupt by its increase. Also, the 3D-surface is dropping very
uniformly, confirming the insignificance of the water phase pH influence on the I/impF
value. By analyzing the results from Table II and the 3D-graph in Fig. 3, more than one
acceptable condition could be selected. For example experiments 1, 5 and 7 gave the op-
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Table I. Plan of the experiments and obtained results
A B C qI/impF
50.00 (–1) 2.50 (–1)a 30.00 (0) 1.0000
70.00 (+1) 2.50 (–1) 30.00 (0) 0.0000
50.00 (–1) 4.50 (+1) 30.00 (0) 1.0000
70.00 (+1) 4.50 (+1) 30.00 (0) 0.0000
50.00 (–1) 3.50 (0) 25.00 (–1) 1.0000
70.00 (+1) 3.50 (0) 25.00 (–1) 0.0000
50.00 (–1) 3.50 (0) 35.00 (+1) 1.0000
70.00 (+1) 3.50 (0) 35.00 (+1) 0.0000
60.00 (0) 2.50 (–1) 25.00 (–1) 0.9744
60.00 (0) 4.50 (+1) 25.00 (–1) 0.9973
60.00 (0) 2.50 (–1) 35.00 (+1) 0.9457
60.00 (0) 4.50 (+1) 35.00 (+1) 0.9940
60.00 (0) 3.50 (0) 30.00 (0) 0.9906
60.00 (0) 3.50 (0) 30.00 (0) 0.9865
60.00 (0) 3.50 (0) 30.00 (0) 0.9935
A – concentration of acetonitrile (%); B – pH of the aqueous phase; C – column temperature (°C); qI/impF – q value
of itraconazole and impurity F. Coded values for factor levels in parentheses.
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Table II. Calculated coefficients of the response modela
qI/impF
Coefficient p-value
b0 0.99 < 0.0001b











a y = b0 + b1A + b2B + b3C + b12AB + b13AC + b23AD + b11A2 + b22B2 + b33C
b Significance at p < 0.05.
qI/impF – q value of itraconazole and impurity F.
adj R2 – the modification of R2 which gives a better estimate since it compensates for the addition of variables to
the model.
Fig. 3. 3D graph: qI/impF = f (ACN content in % (V/V), pH of the aqueous phase).
timal value for qI/impF. The 3D graph confirmed that the content of acetonitrile in the mo-
bile phase of 50 % was justified, while pH in the whole investigated region was accept-
able, so final selection was made by the experimentator and it was 2.5.
Method validation
After establishing the optimal separation conditions, the method was subjected to
validation and the robustness, selectivity, linearity, precision, accuracy, limit of detection
and limit of quantification were tested. In this paper, the approach proposed by Vander
Heyden et al. (6) was applied for the robustness testing. The first step in this approach
comprises selection of the factors to be tested. In the given analytical case, pH of the
aqueous phase was taken as the quantitative, acetonitrile and column temperature as
mixture-related and flow rate as the process variable. Further, factor levels were defined
and are presented in Table IIIA. All chosen factors have a lower (–1) and an upper value
(+1) and they are defined symmetrically around the nominal level (0). As far as the fac-
tor analysis is concerned, fractional factorial 24–1 design was chosen and the plan with 8
experiments was set for the investigation of four factors. In order to evaluate the linea-
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Table IIIA. Robustness testing
A B C D PimpB PI PimpF
48 (–1)a 2.3 (–1)a 28 (–1)a 0.9 (–1)a 49.053 9304.350 47.656
52 (+1) 2.3 (–1) 28 (–1) 1.1 (+1) 39.125 7569.500 37.766
48 (–1) 2.7 (+1) 28 (–1) 1.1 (+1) 41.595 7819.900 37.298
52 (+1) 2.7 (+1) 28 (–1) 0.9 (–1) 61.274 9570.850 51.771
48 (–1) 2.3 (–1) 32 (+1) 1.1 (+1) 39.788 7705.070 35.944
52 (+1) 2.3 (–1) 32 (+1) 0.9 (–1) 46.291 9349.400 49.09
48 (–1) 2.7 (+1) 32 (+1) 0.9 (–1) 49.488 9411.690 43.564
52 (+1) 2.7 (+1) 32 (+1) 1.1 (+1) 98.135 8049.720 39.554
50 (0) 2.5 (0) 30 (0) 1.0 (0) 40.467 8340.430 40.514
50 (0) 2.5 (0) 30 (0) 1.0 (0) 40.740 8499.770 41.024
50 (0) 2.5 (0) 30 (0) 1.0 (0) 40.319 8374.580 40.137
Table IIIB. Factor effects and Ecritical
Factors PimpB PI PimpF
A 16.23 74.5 3.43
B 19.06 231.5 0.43
C 10.66 63.0 –1.58
D 3.13 –1623.0 –10.38
Ecritical (a = 0.05) 38.015 461.524 6.982
A – concentration of acetonitrile (%); B – pH of the aqueous phase; C – column temperature (°C); D – flow rate
(mL min–1); PimpB – peak area of impurity B; PI – peak area of itraconazole, PimpF – peak area of impurity F.
Coded values for factor levels in parentheses.
rity of the responses in the investigated range, three replications were added. The plan
for the conduction of 11 experiments was defined using Design Expert 7.0 software
(Table III).
This step was followed by the definition of the responses that will facilitate the pro-
cess of drawing relevant conclusions. The final goal of the proposed method is to quantify
the analyzed substances and the authors have chosen responses which characterize
quantification: PimpB – peak area of impurity B, PI – peak area of itraconazole and PimpF –
peak area of impurity F. The experiments were conducted based on IIIA and the obtained
results are presented in the same table. At the next step, effects were calculated using
Design Expert 7.0 and the values calculated for factor effects are given in Table IIIB.
The impact of the investigated factors on the method’s robustness can be weighted
after graphical and statistical evaluation of the calculated factor effects. It is recommend-
able to use both approaches and compare the obtained results. In this study, first graphi-
cal evaluation by Pareto charts (Fig. 4) is presented for the estimation of the effects.
Pareto charts estimate factor effects splitting the significant and non-significant ones
by statistical t-line. Factor effects that are higher than the t value are significant and the
obtained results are presented in Table IV.
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Fig. 4. Pareto charts PimpB, PI and PimpF,
t-value = 2.44.
After graphical estimation, statistical evaluation, which is considered more precise
and allows definition of limits for a certain factor, was employed. In the present study,
the authors have chosen evaluation by the algorithm of Dong. This approach is based on
initial estimation of the error based on the effect distribution and followed by calcula-
tion of the margin of error value (ME). ME corresponds to the critical effect; therefore all
effects exceeding ME are considered important. Detailed equations and definitions are
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Table IV. Significance of factor effects





D – flow rate (mLmin–1); PimpB – peak area of impurity B; PI – peak area of itraconazole; PimpF – peak area of impurity F.
Fig. 5. Representative chromatograms obtained under optimal chromatographic conditions of: a)
laboratory mixture containing 200 mg mL–1 of itraconazole (tr = 10.232 min) and 1 mg mL–1 of each
impurity (tr = 5.413 min for impurity B and tr = 11.403 min for impurity F); b) placebo mixture;




given in Vander Heyden et al. (6) and Maskovic et al. (7). The obtained critical effects for
the investigated system are presented in Table III. If the factor effect value is lower than
Ecritical, the influence of that factor on the method’s performance is not significant. The
significance of the effects evaluated statistically is given in Table IV.
As it can be seen from Table IV, the most influential factor is D (flow rate), which is
an operational factor and its change is not expected due to the utilization of the modern
HPLC system. In general, a method could be considered robust if changes of factors in
defined ranges do not influence the responses.
The next parameter that was tested for the purpose of proper validation was selecti-
vity. In Fig. 5. chromatograms of the laboratory mixture, placebo and analyzed sample
are given. From the chromatogram of placebo it is obvious that no significant interfering
peaks at the analyzed compounds retention times were observed and therefore the selec-
tivity was proved.
Linear relationships of the peak area over the mentioned concentration range for
itraconazole and impurities B and F were obtained. All linearity parameters values (Table
V) are within the linearity criteria which state R = 0.995 for active ingredients and R = 0.99
for impurities, and both cases tb was less than ttab.
Important statistical parameters for the method precision evaluation were also con-
sidered. The calculated values of relative standard deviations (RSD) were 0.2 % for itra-
conazole and B 4.1 % for impurity. The obtained values fulfill suggested criteria (27).
To evaluate the model accuracy of the proposed method, the recovery values for la-
boratory mixtures were calculated. Recovery value for itraconazole was 98–102 % and
that for impurities B and F 80–120 % (Table V).
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Table V. Important parameters for linearity and accuracy
Parameter Itraconazole Impurity B Impurity F
Linearity
a 42.63 89.78 59.91
b 41.92 1.05 0.56
R 0.9999 1.0000 1.0000
tb 0.617 3.083 1.726
Accuracy
Concentration 1 (µg mL–1) 160 0.8 0.8
Recovery 1 (%) 101.2 98.5 94.3
Concentration 2 (µg mL–1) 200 1.0 1.01
Recovery 2 (%) 104.3 99.9 96.7
Concentration 3 (µg mL–1) 240 1.2 1.2
Recovery 3 (%) 105.1 95.0 97.6
a – slope, b – intercept, R – correlation coefficient; tb – t value for the intercept: ttab. = 22.571 (p = 0.05, n = 5) for
itraconazole, and ttab. = 4.03 (p = 0.01, n = 5) for impurities.
Limit of detection and limit of quantification were experimentally determined. The
signal-to-noise ratio of 3:1 and 10:1 were taken as LOD and LOQ, respectively, and were
further confirmed by taking dilutions from the secondary stock solution till the peak area
obtained was 3 (for LOD) and 10 (for LOQ) fold the standard deviation of six determina-
tions. For impurity B LOQ is 0.05 g mL–1 and LOD is 0.01 g mL–1, while for the im-
purity F LOQ is 0.1 g mL–1 and LOD is 0.05 g mL–1.
In order to prove the applicability of the developed method, sample solutions of two
different commercially available batches were prepared and analyzed. In these two batches,
the average mass of itraconazole was 10.43 mg per tablet, 0.023 mg per tablet of impu-
rity B which is 0.23 % of the claimed itraconazole content. The content of impurity F was
lower than the limit of detection.
CONCLUSIONS
For optimization and validation of the RP-HPLC method, suitable for the determi-
nation of itraconazole and its impurities B and F in pharmaceutical preparations, appro-
priate experimental designs were used. The optimization step was supported by the Box-
-Behnken design and simultaneous influence of acetonitrile content in the mobile phase,
pH of the aqueous phase and the column temperature on the I/impF was evaluated. At
the beginning of method validation, fractional factorial 24–1 design was selected for ro-
bustness testing and the flow rate of the mobile phase was identified as a factor that in-
fluences the method significantly. Finally, all the other validation parameters were eva-
luated and the adequacy of the developed method was completely confirmed. Although
the method described in this paper is the most appropriate for particular situation, it can
be a very useful starting point in a situation when one has to analyze itraconazole and
more than the two mentioned impurities.
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